SlateXpace provides flexibility, speed to market, and budget control to allow companies to quickly deliver multiple therapies to patients, according to the company. The suite-based platform manages every aspect of advanced therapy medicinal product (ATMP) manufacturing, from facility fabrication and delivery, equipment selection and installation, to start-up, qualification and operator training.

Using SlateXpace, a product can be run in one modality, then after decontamination, users can swap out single-use and mobile equipment and run a new batch in the same space -- in a different modality -- within a few weeks. Modalities that are currently supported by the platform include vaccines, monoclonal antibodies, viral vectors, plasmids, allogeneic cell therapies, and autologous cell therapies.

Is 'bespoke' therapy the future of genomic medicine?
Gene therapies hold extremely exciting promise for meeting the unmet needs of many individuals with genetic diseases, as discussed in a session of the...

Endo to provide fill-finish services for Novavax COVID-19 vaccine
Par Sterile Products has entered a nonexclusive agreement with Novavax to provide fill-finish manufacturing services at its Rochester, MI, plant for Novavax's...

Pfizer to manufacture Vivet's gene therapy
Vivet Therapeutics and Pfizer have entered into a manufacturing agreement where Pfizer will provide clinical supply for a phase I/II clinical trial evaluating...

Samsung Biologics, AstraZeneca ink manufacturing deal
Samsung Biologics and AstraZeneca have signed a $330.8 million long-term supply agreement.

Bio-Techne rebrands genome engineering as part of R&D Systems portfolio
Bio-Techne has rebranded its cell and gene engineering product offer as part of its R&D Systems biotechnology brand.